Categories: AppCareDrugOptimizePersonalPlatformTechnologyTimeUniversity
Axithra is a spin-off from Ghent University and imec, developing a platform to quickly and accurately measure and monitor drug concentrations in blood, paving the way for treatments tailored to the specific needs of each individual, at any given time. The first application is focusing on personalizing beta-lactam antibiotics treatments in the intensive care unit. The company’s platform is based on proprietary optical and photonics technology and will allow physicians to optimize patient care by enabling personalized treatments.
Investors 3
Funding Rounds 1
| Date | Series | Amount | Investors |
| 07.09.2023 | Seed | $10.7M | - |
Mentions in press and media 3
| Date | Title | Description |
| 26.06.2025 | Capitainer strengthens board to accelerate global growth | Capitainer strengthens board to accelerate global growth
Thu, Jun 26, 2025 10:50 CET Report this content
Capitainer AB has appointed a new Board of Directors as the company accelerates its international expansion and scales up to meet growi... |
| 07.01.2025 | The next wave of innovation: 10 promising Belgian startups to keep an eye on in 2025 | The startup ecosystem in Belgium is very mature, signs are the increasing size of funding rounds, growing international investor participation, and frequent unicorns. A strong support network of incubators, accelerators, and venture funds b... |
| 07.09.2023 | Axithra raises € 10 million in Seed funding | Leuven and Ghent (Belgium), 5 September, 2023 – Axithra, a new spin-off of imec and Ghent University, today announced a 10 million euro seed round, securing the first two years of R&D. Axithra develops a technology platform for therapeu... |
Reviews 0
